Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 31:13:285-298.
doi: 10.1515/biol-2018-0035. eCollection 2018 Jan.

Nanoparticles as Carriers of Proteins, Peptides and Other Therapeutic Molecules

Agnieszka Pudlarz  1 , Janusz Szemraj  1
Affiliations

Nanoparticles as Carriers of Proteins, Peptides and Other Therapeutic Molecules

Agnieszka Pudlarz et al. Open Life Sci. .

Abstract

Nanoparticles have many applications both in industry and medicine. Depending upon their physical and chemical properties, they can be used as carriers of therapeutic molecules or as therapeutics. Nanoparticles are made of synthetic or natural polymers, lipids or metals. Their use allows for faster transport to the place of action, thus prolonging its presence in the body and limiting side effects. In addition, the use of such a drug delivery system protects the drug from rapid disintegration and elimination from the body. In recent years, the use of proteins and peptides as therapeutic molecules has grown significantly. Unfortunately, proteins are subject to enzymatic digestion and can cause unwanted immune response beyond therapeutic action. The use of drug carriers can minimize undesirable side effects and reduce the dose of medication needed to achieve the therapeutic effect. The current study presents the use of several selected drug delivery systems for the delivery of proteins, peptides and other therapeutic molecules.

Keywords: Nanoparticles; active transport; carriers; drug delivery systems; protein carriers.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Authors state no conflict of interest.

Figures

Figure 1
Figure 1
A schematic illustration showing passive and active transport of nanocarrier with a drug to the target cell.
Figure 2
Figure 2
Examples of nanoparticle drug delivery systems.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barry JN, Vertegel AA. Nanomaterials for Protein Mediated Therapy and Delivery. Nano Life. 2013;3(4):1. –. - PMC - PubMed
    1. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16. - PMC - PubMed
    1. Nevozhay D, Kańska U, Budzyńska R, Boratyński J. Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases. Postepy Hig Med Dosw. 2007;61:350. –. - PubMed
    1. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Phaemacological Reports. 2012;64:1020. –. - PubMed
    1. Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: Overview and perspectives. J Control Release. 2016;240:24. –. - PMC - PubMed

LinkOut - more resources